**[investwise]** Granules India-Excellent Performance (BUY)-FY10 EPS Rs 15, Div 12.5%, PE 7

 

Non Banking Description Amount(Rs. in lakhs) Net Sales/Income from Operations 46108.93 Other Operating Income - Increase/Decrease in Stock in trade and work in progress 258.13 Consumption of Raw Materials 28357.91 Purchase of traded goods - Employees Cost 2789.51 Depreciation 1857.44 Other Expenditure 7438.77 Total Expenditure 40701.76 Profit from Operations before Other Income, Interest & Exceptional Items 5407.17 Other Income 107.36 Profit before Interest & Exceptional Items 5514.53 Interest 1754.90 Profit after Interest but before Exceptional Items 3759.63 Exceptional items - Profit(+)/Loss(-) from Ordinary Activities before tax 3759.63 Tax Expense 722.42 Net Profit(+)/Loss(-) from Ordinary Activities after tax 3037.21 Extraordinary Items - Net Profit (+) / Loss (-) for the period 3037.21 Minority Interest - Shares of Associates - Other Related Items - Consolidated Net Profit (+) / Loss (-) for the period 3037.21 Dividend (%) - Face Value (in Rs.) 10.00 Paid-up Equity Share Capital 2005.72 Reserves excluding Revaluation Reserves - Basic EPS before Extraordinary items (in Rs.) 15.14 Diluted EPS before Extraordinary items (in Rs.) 15.14 Basic EPS after Extraordinary items (in Rs.) 15.14 Diluted EPS after Extraordinary items (in Rs.) 15.14 Public Shareholding (Number of Shares) 12557075.00 Public Shareholding (%) 62.61 Promoter & Promoter group Number of Shares Pledged / Encumbered 858000.00 Promoter & Promoter group Shares Pledged / Encumbered (as a % of total shareholding of Promoter and Promoter Group) 12.39 Promoter & Promoter group Shares Pledged / Encumbered (as a % total share capital of the company) 4.28 Promoter & Promoter group Number of Shares Non-encumbered 6069039.00 Promoter & Promoter group Shares Non-encumbered (as a % of total shareholding of Promoter and Promoter Group) 87.61 Promoter & Promoter group Shares Non-encumbered (as a % total share capital of the company) 30.25 Remarks: 1.Other Expenditure= Other Expenditure of Rs. 62.95 lacs + R & D Expenses of Rs. 367.07 lacs + Selling and Distribution Expenses of Rs. 3090.65 lacs + Administrative Expenses of Rs. 1575.3 lacs + Manufacturing Expenses of Rs. 3463.91 lacs + Foreign Exchange (Gain)/Loss of Rs. -1121.11 lacs. 2. The company operates only in the segment of Pharmaceuticals. Safe Harbor Statement: Some forward looking statements on projections, estimates, expectations & outlook are included to enable a better comprehension of the Company prospects. Actual results may, however, differ materially from those stated on account of factors such as changes in government regulations, tax regimes, economic developments within India and the countries within which the Company conducts its business, exchange rate and interest rate movements, impact of competing products and their pricing, product demand and supply constraints.   Nothing in this article is, or should be construed as, investment advice.

__._,_.___

Reply to sender | Reply to group | Reply via web post | Start a new topic

Messages in this topic (1)

Recent Activity:

• New Members 2

Visit Your Group

*****************************************
http://in.groups.yahoo.com/group/investwise/

INVESTMENTS IN INDIA
We are low-risk, long-term investors. 

Stocks, mutual funds and the entire investment gamut.  Only financing/investment avenues in India will be discussed. 

For any assistance, questions or improvement ideas, contact investwise-owner@yahoogroups.co.in

****************************************************************

NEW! ==== Check our LINKS and FILES sections for a world of information. REGULARLY UPDATED.

NEW! ==== Check "Tracklist" in Links and Files sections for Investment Ideas.

****************************************************************

Switch to: Text-Only, Daily Digest • Unsubscribe • Terms of Use

.

__,_._,___